Comparison of performance between Fast Track Diagnostics Respiratory Kit and the CDC global reference laboratory for influenza rRT-PCR panel for detection of influenza A and influenza B

Assana Cissé1 | Jennifer Milucky2 | Abdoul Kader Ilboudo1 | Jessica L. Waller2 | Brice Bicaba3 | Isaïe Medah3 | Sara Mirza2 | Cynthia G. Whitney2 | Zekiba Tarnagda1

Abstract

Background: Reliable diagnostics are a key to identifying influenza infections.

Objectives: Our objectives were to describe the detection of influenza among severe acute respiratory infection (SARI) cases, to compare test results from the Fast Track Diagnostics (FTD) Kit for influenza detection to the Centers for Disease Control (CDC) human influenza virus detection and characterization panel, and to assess seasonality of influenza in Burkina Faso.

Methods: Nasopharyngeal and oropharyngeal specimens from SARI cases (hospitalized patients with fever, cough, and onset in the previous 10 days) were tested using the FTD-33 Kit and the CDC rRT-PCR influenza assays. We assessed sensitivity and specificity of the FTD-33 Kit for detecting influenza A, influenza B, and the influenza A(H1N1)pdm09 strain using the CDC human influenza rRT-PCR panel as the gold standard.

Results: From December 2016 to February 2019, 1706 SARI cases were identified, 1511 specimens were tested, and 211 were positive for influenza A (14.0%) and 100 for influenza B (6.6%) by either assay. Higher influenza circulation occurred between November and April with varying peaks of influenza A and influenza B. Sensitivity of the FTD-33 assay was 91.9% for influenza A, 95.7% for influenza B, and 93.8% for A(H1N1)pdm09 subtype. Specificity was over 99% for all three tests.

Conclusions: Our study indicates that Burkina Faso has one peak of influenza each year which is similar to the Northern Hemisphere and differs from other countries in West Africa. We found high concordance of influenza results between the two assays indicating FTD-33 can be used to reliably detect influenza among SARI cases.

KEYWORDS

Burkina Faso, diagnostics, influenza, severe acute respiratory infections, West Africa

Received: 3 August 2020 | Revised: 6 November 2020 | Accepted: 12 November 2020
DOI: 10.1111/irv.12830

© 2021 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.

Influenza Other Respi Viruses. 2021:15:381–388.
Influenza viruses cause acute respiratory infections in all parts of the world and can lead to hospitalization and death. An estimated 5%-10% of adults and 20%-30% of children worldwide are affected by seasonal influenza each year. A recent model by Iuliano et al. estimated that 4-8.8 per 100000 influenza-associated deaths occur annually around the world, with the highest rates occurring in sub-Saharan Africa, the western Pacific, and South-East Asia. Surveillance for influenza that includes accurate laboratory diagnostics plays a critical role for annual vaccine strain selection, identification of novel strains, and quick recognition of increased influenza circulation that could signal a pandemic. One report on the seasonality of influenza which included influenza-like illness (ILI) and/or severe acute respiratory infection (SARI) surveillance in eight West African countries described two peaks; however, data included in this report from Burkina Faso did not include SARI cases, and country-specific seasonality was limited.

Clinical presentation of influenza is similar to that of many other viral, bacterial, and fungal pathogens causing acute respiratory illnesses; thus, diagnostics play a key role in identifying which acute respiratory infections are caused by influenza. The Centers for Disease Control and Prevention (CDC) reverse transcription quantitative PCR (rRT-PCR) assay for detection and characterization of influenza is utilized in influenza reference laboratories around the world and is considered a reliable standard for influenza testing by the World Health Organization. Respiratory illnesses are caused by a variety of pathogens, and incorporating multi-pathogen diagnostic methods into respiratory disease surveillance platforms can help ministries of health determine potential causes of outbreaks or know when respiratory pathogens are circulating. Fast Track Diagnostics Respiratory Pathogens 33 Respiratory (FTD-33) Kit is a multi-pathogen platform using real-time reverse-transcriptase polymerase chain reaction (rRT-PCR) to detect 33 pathogens in humans with acute respiratory illness. It is important that the individual targets in a multipathogen platform perform well compared with single-target assays.

Burkina Faso is a sub-Saharan country in West Africa with a population of approximately 20 million people. One of the leading causes of death is lower respiratory tract infections, which account for more than 14% of deaths annually. The country implemented a sentinel surveillance system of ILI in 2010 and in late 2016, began conducting SARI sentinel surveillance to better understand respiratory pathogens circulating and their disease burden among the community. The country has a national influenza reference laboratory with established capacity to conduct influenza testing using the CDC panel and multipathogen testing using the FTD-33 Kit. Our objectives were to describe the circulation of influenza among SARI cases in Burkina Faso and to determine sensitivity and specificity of the FTD-33 Kit for influenza detection compared with the CDC human influenza rRT-PCR detection and characterization panel.

2 | METHODS

2.1 | Study sites and data collection

SARI sentinel surveillance was conducted among inpatients of all ages at one national teaching hospital (Centre Hospitalier Universitaire de Bogodogo [Bogodogo CHU]) and three district hospitals: Boussé Centre Médical avec Antenne Chirurgicale de Kongoussi (Kongoussi CMA), Centre Médical avec Antenne Chirurgicale de Houndé (Houndé CMA), and Centre Médical avec Antenne Chirurgicale de Boussé (Boussé CMA). Bogodogo CHU is a large hospital located in the capital city of Ouagadougou. Boussé CMA is located in the Plateau-Central region; Kongoussi CMA is located in the Centre-Nord Region; and Houndé CMAs located in the Hauts-Bassins Region on the western side of the country. Cases were identified using the World Health Organization SARI case definition (an acute respiratory infection with history of fever or measured fever ≥38°C and cough, with onset within the last 10 days, and requiring hospitalization). Trained hospital staff identified cases 7 days a week throughout the study time frame and completed a report form for each identified case that included information on demographics, symptoms of the illness, treatment administered during the hospitalization, and outcome.

Nasopharyngeal (NP) and oropharyngeal (OP) specimens were collected from SARI cases within 24 hours of hospitalization when possible and placed together into one tube of Universal Transport Media (Copan Diagnostics). Only NP swabs were collected from children <6 months of age. Immediately following collection, specimens were refrigerated at four degrees Celsius for temporary storage. Specimens were then transported on cold packs to the national reference laboratory within 72 hours of specimen collection. Upon arrival at the national reference laboratory, specimens were aliquoted and either tested immediately or stored at −80 degrees Celsius until testing could be completed.

2.1.1 | Laboratory testing methods

Nucleic acid extraction

Total nucleic acid (TNA) was extracted from 400 µL of Universal Transport Media containing the NP and OP specimens and eluted into 110 µL using the EZ1 Advanced XL Instrument with the EZ1 Mini Viral 2.0 Kit (Qiagen) following the manufacturer’s instructions. Seven specimens were extracted at a time with an extraction control consisting of nuclease-free water.

Respiratory viruses, bacteria, and fungi real-time RT-PCR detection

The TNA extracts from NP/OP specimens were screened individually for detection of respiratory pathogens using eight multiplex reverse-transcriptase real-time polymerase chain reactions (rRT-PCR) from the FTD-33 Test Kit (Fast Track Diagnostics). The kit is used for detection of the following respiratory viruses, bacteria, and fungi: influenza A, influenza A subtype A(H1N1)pdm09, influenza B, and...
influenza C; parainfluenza viruses 1, 2, 3, and 4; coronaviruses NL63, 229E, OC43, and HKU1; human metapneumoviruses A and B; rhinovirus; respiratory syncytial viruses A and B; adenovirus; enterovirus; parechovirus; bocavirus; Pneumocystis jirovecii; Mycoplasma pneumoniae; Chlamydia pneumoniae; Streptococcus pneumoniae; Haemophilus influenzae; Haemophilus influenzae type B; Staphylococcus aureus; Moraxella catarrhalis; Bordetella species (excluding Bordetella parapertussis); Klebsiella pneumoniae; Legionella species; and Salmonella species.6

The eight multiplex rRT-PCR reactions were set up following the manufacturer’s instructions.6 Each reaction mix consisted of 10 µL TNA, 1.5 µL of oligonucleotide mix, 12.5 µL 2 X AgPath-ID™ One-Step RT-PCR buffer and 1 µL 25 X AgPath-ID™ One-Step RT-PCR Enzyme Mix (Thermo Fisher Scientific). The manufacturer’s instructions recommend introducing exogenous internal control material provided with the FTD-33 Kit into each clinical specimen prior to nucleic acid extraction and testing with corresponding rRT-PCR oligonucleotide mix to monitor for PCR inhibition. This step was excluded to minimize potential contamination of primary specimen material. Instead, each specimen was tested in parallel for the presence of human ribonuclease P (RNase P). Detection of RNase P, which is ubiquitous in human cells, serves as a control for specimen extraction and PCR inhibition without manipulation of primary specimens. Reaction mixtures containing a no-template control, extraction control, and positive control (Resp21 PC or Resp33 PC2) were included for each multiplex reaction mix. An extraction control and no-template control materials were included for testing of the eight multiplex reaction mixes and the RNase P reaction mix. The positive control (Resp21 PC or Resp33 PC2) consisting of pooled plasmids6 from the FTD-33 Kit was also included for testing of the multiplex reaction mix and human DNA was included as the positive control for the RNase P reaction mix. All assays were tested using the Applied Biosystems 7500 Real-Time PCR Instrument (Thermo Fisher Scientific) with the following cycling conditions: 42°C for 15 minutes, 94°C for 3 minutes, 40 cycles of 94°C for 8 seconds, and 60°C for 34 seconds. Any assay or specimen with a control result deviating from the expected result was retested.

2.2 | Statistical analysis

We described the basic demographics of SARI cases and the frequency of influenza A- and influenza B-positive results among SARI cases. Differences in characteristics between groups were assessed using chi-square, with P-values <.05 considered statistically significant. We also assessed sensitivity and specificity of the FTD-33 Kit for detecting influenza A, influenza B, and the influenza A(H1N1)pdm09 strain by comparing results of the FTD-33 Kit to those of the CDC rRT-PCR panel, considering the CDC rRT-PCR panel as the gold standard. Other influenza subtypes are unavailable for comparison in the FTD-33 Kit, and influenza C was not tested by CDC rRT-PCR panel. We also assessed sensitivity and specificity, limiting the cases to those that were collected during months in which there were greater than three specimens positive for influenza A, influenza B, or influenza A (H1N1)pdm09 by either laboratory method. For influenza A, influenza B, and the H1N1 assays, we assessed cycle threshold (ct) values of discordant and concordant results. Analysis of concordant positive results relied on the reported FTD-33 ct value, and analysis of the discordant results relied on the ct value of the positive assay. We conducted chi-square tests to compare the proportion of discordant and discordant results with ct values above and below 30 for the influenza A, influenza B, and H1N1 assays. P-values <.05 were considered statistically significant. Statistical analyses were conducted using SAS version 9.4 (SAS Institute Inc).

3 | RESULTS

From December 2016 to February 2019, 1706 SARI cases were identified across the four sentinel surveillance sites. Among these, 1511 (88.6%) had specimens with available test results for both the FTD-33 and the CDC singleplex assays at the national reference laboratory and were included in this analysis; 30.7% were specimens from Houndé, 30.2% from Kongoussi, 24.3% from Bogodogo, and 14.8% from Boussé (Table 1). Most cases (85.2%) were in children <5 years of age, and more than half (51.9%) were those in between the ages of 1-4 years. Influenza A and influenza B detections among SARI cases occurred more often in older age groups. Cases among persons 5 years of age and older had the highest proportion of influenza A (18.1%) or influenza B (9.1%) detected and cases among infants <1 year of age had the lowest proportion of influenza detections.
CISSÉ et al. (influenza A 10.3%; influenza B 3.7%) (influenza A \( P < .05 \); influenza B \( P < .05 \)). The proportion of samples with influenza detected did not differ by site.

SARI case enrollment peaked in January 2018 with 138 cases across all sites during that month (Figure 1); 87 (63.0%) of those cases tested positive for influenza A by any assay. In general, enrollment of SARI cases was higher during the months of October to March than during other months. Influenza B was circulating at the start of our surveillance in December 2016 and influenza A subtype H1N1 began circulating in March 2017. The second respiratory season had very little influenza B circulation, but there were large peaks of influenza A H1N1 circulation beginning in September 2017 and with a marked increase during December 2017-February 2018. The third respiratory season began with influenza B circulating in August of 2018 followed

![Figure 1](image-url) **Figure 1** Number of severe acute respiratory infections (SARI) cases and number of SARI cases that tested positive (by any assay) for influenza A and influenza B by month and year of symptom onset, December 2016-February 2019.
by influenza A H3N2 circulation in November. As influenza A circulation increased, influenza B circulation decreased. During the months of May to August in 2017 and 2018, very little influenza was detected among our SARI case population.

Overall, 327 (21.6%) specimens were positive for influenza either by FTD-33 or CDC rRT-PCR panel, with 211 (14.0%) positive for influenza A, 100 (6.6%) positive for influenza B, and 16 (1.1%) positive for influenza C (testing available by FTD-33 only; Table 2). All specimens positive for influenza A or influenza B by CDC rRT-PCR panel were subtyped. Most influenza A-positive specimens were virus subtype A(H1N1)pdm09 (81.5%), and most influenza B-positive specimens were virus subtype Victoria lineage (65.0%).

Using the CDC rRT-PCR panel as the gold standard, sensitivity of the FTD-33 assay was 91.9% for influenza A, 95.7% for influenza B, and 93.8% for A(H1N1)pdm09 subtype (Table 3). Specificity was over 99% for all three tests. Sensitivity and specificity of the FTD-33 assay were similar when including only months where influenza was circulating.

Testing identified 29 specimens with discordant results (positive by one assay and negative by the other) for influenza A results, 12 specimens with discordant influenza B results, and 21 specimens with discordant A(H1N1)pdm09 subtype. All specimens with discordant results arrived at the laboratory in good condition (i.e., frozen), and there was no difference in discordant results across site or age-group. Specimens with discordant results were significantly more likely to have a ct value above 30 than those with concordant results for all three assays ($P < .05$; Table 4). Analysis of concordant positive results relied on the reported FTD-33 ct value, and analysis of the discordant results relied on the ct value of the positive assay. For the influenza A and influenza A(H1N1)pdm09 subtype assays, discordant results were equally likely to be positive for both assays.

### TABLE 2
Results of influenza testing using FTD-33 and the CDC influenza singleplex assays among 1511 specimens from patients with severe acute respiratory infections, December 2016-February 2019

|          | FTD-33 positive | CDC singleplex assay positive | Positive by either assay |
|----------|-----------------|-----------------------------|--------------------------|
|          | N   | %   | N   | %   | N   | %   |
| Influenza A | 195 | 12.9% | 198 | 13.1% | 211 | 14.0% |
| Subtype A(H1N1)pdm09 | 162 | 10.8% | 161 | 10.7% | 172 | 11.4% |
| Subtype H3N2  | NA  | NA   | 37  | 2.5%  | 37  | 2.5%  |
| Influenza B  | 96  | 6.4%  | 92  | 6.1%  | 100 | 6.6%  |
| Subtype Victoria | NA  | NA   | 65  | 4.3%  | 65  | 4.3%  |
| Subtype Yamagata | NA  | NA   | 25  | 1.7%  | 25  | 1.7%  |
| Influenza C  | 16  | 1.1%  | NA  | NA    | 16  | 1.1%  |

NA - Not applicable

### TABLE 3
Sensitivity and specificity of FTD-33 influenza assays compared to the CDC influenza assays from all study months (December 2016-February 2019) and during only those months with influenza circulating (>3 positive tests)

| Results from singleplex assay | N tested | FTD+ | FTD- | Sensitivity | Specificity | Confidence intervals | P value |
|-----------------------------|----------|------|------|------------|-------------|----------------------|---------|
| All months                  |          |      |      |            |             |                      |         |
| Influenza A positive        | 198      | 182  | 16   | 91.9%      | 99.0%       | 0.87-0.96            | <.0001  |
| Influenza A negative        | 1308     | 13   | 1295 | 95.7%      | 99.0%       | 0.89-0.99            | <.0001  |
| Influenza B positive        | 92       | 88   | 4    | 95.7%      | 99.0%       | 0.89-0.99            | <.0001  |
| Influenza B negative        | 1412     | 8    | 1404 | 99.4%      | 99.0%       | 0.89-0.99            | <.0001  |
| A(H1N1)pdm09 positive       | 161      | 151  | 10   | 93.8%      | 99.0%       | 0.89-0.99            | <.0001  |
| A(H1N1)pdm09 negative      | 1343     | 11   | 1332 | 99.2%      | 99.0%       | 0.98-0.99            | <.0001  |
| Months with influenza circulating\(^a\) |          |      |      |            |             |                      |         |
| Influenza A positive        | 190      | 175  | 15   | 92.1%      | 99.0%       | 0.87-0.96            | <.0001  |
| Influenza A negative        | 457      | 11   | 446  | 97.6%      | 97.6%       | 0.96-0.98            | <.0001  |
| Influenza B positive        | 79       | 76   | 3    | 96.2%      | 96.2%       | 0.89-0.99            | <.0001  |
| Influenza B negative        | 427      | 8    | 419  | 98.1%      | 98.1%       | 0.96-0.99            | <.0001  |
| A(H1N1)pdm09 positive       | 184      | 174  | 10   | 94.6%      | 94.6%       | 0.89-0.99            | <.0001  |
| A(H1N1)pdm09 negative      | 362      | 11   | 351  | 97.0%      | 97.0%       | 0.95-0.99            | <.0001  |

\(^a\)Results for all specimens during a month were included if >3 specimens tested positive for the target of interest (e.g., influenza A, influenza B, or H1N1) with the singleplex assay.
however, for influenza B, discordant results were more frequently positive with the FTD-33 Kits (8 of 12 discordant results).

4 | DISCUSSION

Our study found that the results for influenza A, influenza B, and A(H1N1)pdm09 assays for FTD-33 and the CDC rRT-PCR panel were similar. In particular, concordance of testing results was very good when there was a higher viral load (lower ct value) in the specimen. We reported sensitivity of greater than 93% and specificity of greater than 99% for all three assays. Other studies have reported on sensitivity and specificity or concordance of the FTD-33 assay compared with either other multipathogen platforms or in-house singleplex tests.8-13 Most of these studies reported comparable results for the influenza A, influenza B, and H1N1 assays; however, two reported significant discrepancies with the influenza B assay.8,10 Most specimens with discordant results had higher ct values, closer to the limit of detection; thus, discordant results were not unexpected given the lower concentrations of virus in the specimens. We did not find that these results differed by age-group or site, and all discordant specimens arrived in the laboratory in good condition.

We also found that in Burkina Faso, a country with distinct dry and rainy seasons, influenza did not circulate year-round, but rather circulated primarily during the same months as influenza circulation in Northern Hemisphere countries. A publication summarizing influenza-like illness and SARI surveillance data across eight West African countries, including Burkina Faso, reported year-round circulation of influenza with two distinct peaks of circulation (January-March and August-November) which differs from our findings.3 However, over the 3-year study period, only 1009 influenza-like illness cases and no SARI cases from Burkina Faso were included in that analysis limiting the overall contribution of cases from Burkina Faso included in the analysis. Additionally, overall percent of influenza positives was much higher in our study which may indicate there are differences in individuals captured using an influenza-like illness case definition vs a SARI case definition. An understanding of seasonality of influenza within the country can inform seasonal influenza vaccine policy and pandemic preparedness. Further assessment of the surveillance system will allow the country to identify groups at risk for influenza and can inform clinical management of cases. Additionally, use of the FTD-33 assay for SARI surveillance allows for detection of other pathogens when influenza is not detected as well as co-detections with influenza.

There are some limitations to our study. Our comparisons of influenza results were limited to influenza A, influenza B, and A(H1N1)pdm09 subtype. There is no FTD-33 assay for influenza A subtype H3N2 or influenza B lineages for comparison, and there was no CDC assay for influenza C available. Study staff were trained multiple times on specimen collection techniques; however, during busy respiratory months the clinical staff may have missed SARI cases due to other clinical responsibilities which may

### Table 4: Cycle threshold (ct) values ≥30 among specimens with concordant and discordant positive results cases for influenza A, influenza B, and H1N1 subtype by FTD-33 and CDC influenza assays

|   | Concordant results | Discordant results | P value |
|---|--------------------|--------------------|---------|
|   | Number of specimens | Number of specimens | Percent of specimens |
|   | with ct value ≥30 | with ct value ≥30 | with ct value ≥30 |
| Influenza A | 182 | 44 | 24.2% |
| Influenza B | 88 | 17 | 19.3% |
| A(H1N1)pdm09 | 151 | 55 | 36.4% |

8 Analysis of concordant positive results relied on the reported FTD-33 ct value.
9 Analysis of the discordant results relied on the ct value of the positive assay.
have implications for the number of influenza cases identified during peak seasons. We were unable to include detection of additional respiratory pathogens in this report. A further investigation of additional pathogen detections would provide additional information about other respiratory pathogens circulating in this population.

5 CONCLUSION

FTD-33 allows for rapid detection of 33 respiratory pathogens, and laboratorians were able to conduct the complex testing in a timely and efficient manner that provided accurate test results for detection of influenza. Additionally, multiplex methods reduce the amount of specimen volume needed to test for the large number of pathogens. However, management of data from multipathogen platforms remains a challenge, especially for surveillance purposes. Our study showed similar results between FTD-33 and the CDC rRT-PCR panel and highlights a seasonality of influenza circulation similar to that of the Northern Hemisphere during the 27 months of SARI case enrollment. Further assessment of epidemiologic and clinical characteristics of influenza cases will allow for public health officials to better understand risk groups and implement vaccine policies.

ACKNOWLEDGEMENTS

We would like to thank the District Chief Doctors (MCDs), Centre d’Information Sanitaire et de Surveillance Epidémiologique (CISSÉs), Directorate of Population Health Protection (DPSP), General Directorate of Public Health (DGSP), African Society for Laboratory Medicine (ASLM), and DAVYCAS International for supporting the surveillance system. We would like to thank Romuald Koama, Diane Somda, Hato Zapan, and Armel Sanou for their assistance in laboratory testing. We would like to thank Tyler Burbridge for development of a laboratory database to manage a large amount of data.

CONFLICT OF INTEREST

The authors have no potential conflicts to disclose.

DISCLAIMER

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

AUTHOR CONTRIBUTION

Assana Cisse: Data curation (equal); Formal analysis (equal); Investigation (equal); Project administration (equal); Software (equal); Validation (equal); Writing-review & editing (equal). Jennifer Milucky: Conceptualization (lead); Data curation (lead); Formal analysis (lead); Funding acquisition (supporting); Investigation (equal); Methodology (equal); Project administration (equal); Resources (supporting); Software (equal); Supervision (equal); Validation (lead); Visualization (lead); Writing-original draft (lead); Writing-review & editing (equal). Abdoul K. Ilboudo: Data curation (equal); Investigation (equal); Project administration (equal); Software (equal); Validation (equal); Writing-review & editing (equal). Jessica Waller: Data curation (equal); Formal analysis (supporting); Investigation (equal); Methodology (equal); Project administration (equal); Resources (supporting); Validation (supporting); Writing-original draft (supporting); Writing-review & editing (equal). Brice Bicaba: Conceptualization (supporting); Data curation (supporting); Funding acquisition (supporting); Investigation (supporting); Project administration (supporting); Resources (supporting); Supervision (equal); Writing-review & editing (equal). Isaïe Médah: Conceptualization (supporting); Funding acquisition (equal); Resources (equal); Supervision (equal); Writing-review & editing (equal). Cynthia Whitney: Conceptualization (equal); Investigation (equal); Methodology (equal); Resources (supporting); Supervision (equal); Writing-review & editing (equal). Zekiba Tarnagda: Conceptualization (supporting); Funding acquisition (supporting); Investigation (equal); Methodology (equal); Resources (supporting); Supervision (lead); Writing-review & editing (equal).

DATA AVAILABILITY STATEMENT

Data may be available pending approval from the Burkina Faso Ministry of Health.

ORCID

Jennifer Milucky https://orcid.org/0000-0002-1491-4669

REFERENCES

1. The World Health Organization. Seasonal Influenza, 2019; https://www.who.int/ith/diseases/influenza_seasonal/en/. Accessed June 12, 2019.
2. Iuliano AD, Roguski KM, Chang HH, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet (London, England). 2018;391(10127):1285-1300.
3. Talla Nzussouo N, Duque J, Adedeji AA, et al. Epidemiology of influenza virus real-time RT-PCR detection and characterization panel. BMC Infect Dis. 2017;17(1):745.
4. Centers for Disease Control and Prevention. CDC human influenza virus real-time RT-PCR detection and characterization panel. September 26, 2008.
5. The World Health Organization. WHO information for the molecular detection of influenza viruses. July 2017. https://www.who.int/influenza/gisrs_laboratory/WHO_information_for_the_molecular_detection_of_influenza_viruses_20171023_Final.pdf?ua=1. Accessed September 15, 2018.
6. Fast Track Diagnostics. FTD respiratory pathogens 33 manual. Vol FTD 2P2 – 32_64 – MANUAL- v1-2015_10 EN. Luxembourg: Fast Track Diagnostics; 2015.
7. World Health Organization. Countries Burkina Faso. 2016; http://www.who.int/countries/bfa/en/. Accessed November 2019.
8. Kenmoe S, Tcharnenwa C, Monamele GC, et al. Comparison of FTD(R) respiratory pathogens 33 and a singleplex CDC assay for the detection of respiratory viruses: a study from Cameroon. Diagn Microbiol Infect Dis. 2019;94(3):236-242.
9. Malhotra B, Swamy MA, Reddy PV, Kumar N, Tiwari JK. Evaluation of custom multiplex real time RT-PCR in comparison to Fast Track
Diagnostics Respiratory 21 Pathogens Kit for detection of multiple respiratory viruses. Virol J. 2016;13:91.

10. Salez N, Vabret A, Leruez-Ville M, et al. Evaluation of four commercial multiplex molecular tests for the diagnosis of acute respiratory infections. PLoS One. 2015;10(6):e0130378.

11. Anderson TP, Werno AM, Barratt K, Mahagamasekera P, Murdoch DR, Jennings LC. Comparison of four multiplex PCR assays for the detection of viral pathogens in respiratory specimens. J Virol Methods. 2013;191(2):118-121.

12. Driscoll AJ, Karron RA, Bhat N, et al. Evaluation of Fast Track diagnostics and TaqMan array card real-time PCR assays for the detection of respiratory pathogens. J Microbiol Methods. 2014;107:222-226.

13. Sakthivel SK, Whitaker B, Lu X, et al. Comparison of Fast Track Diagnostics Respiratory Pathogens Multiplex Real-Time RT-PCR Assay with in-house singleplex assays for comprehensive detection of human respiratory viruses. J Virol Methods. 2012;185(2):259-266.

How to cite this article: Cissé A, Milucky J, Ilboudo AK, et al. Comparison of performance between Fast Track Diagnostics Respiratory Kit and the CDC global reference laboratory for influenza rRT-PCR panel for detection of influenza A and influenza B. Influenza Other Respi Viruses. 2021;15:381–388. https://doi.org/10.1111/irv.12830